Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from Sanofi Pasteur MSD (manufacturer control # DK-1577272925-2016009198) on 15-SEP-2016. Case received from a physician via HA on 12-Sep-2016 under the reference number DK-DKMA-WBS-0004425. A 14-year-old female adolescent patient received GARDASIL, (batch number Lot unknown, Dose 1) via intramuscular route on 29-Oct-2008, GARDASIL, (batch number Lot unknown, Dose 2) via intramuscular route on 23-Jan-2009, GARDASIL, (batch number Lot unknown, Dose 3) via intramuscular route on 01-Jul-2009. The patient experienced recurrence flu, headache, dizziness, palpitation, nausea, voiding difficulty, frequent bruises, skin disorder, shortness of breath, fatigue, involuntary muscle movement, immunocompromised, light sensitivity, lactose sensitivity, gluten sensitivity, pain in knee, diarrhea, obstipation, spontaneous vomiting, recurrent infection and infection on an unknown date. The patient was admitted to hospital on an unspecified date. The patient''s outcome was reported as Not Recovered/Not Resolved. Case description: The patient states that the first symptoms developed 2-3 months after the 3rd vaccination. She developed recurring flu and infection. The other symptoms have developed subsequently. The patient received her vaccinations in 7th grade and trained gymnastics once weekly and football twice weekly with games on some weekends. As a consequence of her symptoms, the patient doesn''t study. In general, she needs to prioritise her energy due to her symptoms. She turned very light sensitive, which makes it very difficult to e.g. to sports. She developed food allergy, which affects her socially. No other vaccines, other medications are not known.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166